FDA-cleared profile

BriefCase-Quantification

Aidoc Medical, Ltd. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Four-category coronary artery calcification (CAC) assessment of plaques on non-cardiac-gated, non-contrast CT images that include the heart; preview images are informational and the result is not for stand-alone clinical decision-making.

Clinical role
Parallel post-processing CAC categorization, quantification, and visualization support for clinician review.
Images and patients
CT/CTA · Heart and coronary arteries
Key limitation
Keep in mind: Technically inadequate studies, including motion artifacts, severe metal artifacts, or suboptimal/inadequate field of view, are excluded; the comparison table lists axial slice thickness up to 5.0 mm and a 130 HU calcium threshold. Results are preliminary, preview images are non-diagnostic, and clinicians must review full images and other clinical information; the device is not for stand-alone decisions.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Four-category coronary artery calcification (CAC) assessment of plaques on non-cardiac-gated, non-contrast CT images that include the heart; preview images are informational and the result is not for stand-alone clinical decision-making.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Heart and coronary arteries Input: Filtered routine DICOM images from non-cardiac-gated, non-contrast CT studies that include the heart in adults aged 30 years and older.
  • Who uses it?Intended users: Hospital networks and appropriately trained medical specialists (physicians).
  • What does the software produce?Output: Very low, low, medium, or high CAC category corresponding to Agatston ranges 0, 1-100, 101-400, and at least 400; a preliminary report with warnings, category, and number of CAC-containing slices; and PACS images showing the represented calcium alongside original slices.
  • What is its most important limitation?Key limitation: Technically inadequate studies, including motion artifacts, severe metal artifacts, or suboptimal/inadequate field of view, are excluded; the comparison table lists axial slice thickness up to 5.0 mm and a 130 HU calcium threshold. Results are preliminary, preview images are non-diagnostic, and clinicians must review full images and other clinical information; the device is not for stand-alone decisions.

Clinical takeaway. Clinical role: Four-category coronary artery calcification (CAC) assessment of plaques on non-cardiac-gated, non-contrast CT images that include the heart; preview images are informational and the result is not for stand-alone clinical decision-making.

Evidence takeaway. Evidence from the reviewed source record: FDA packet: retrospective, blinded, multicenter pivotal study of 433 cases from 6 U.S. clinical sites, with ground truth finalized by a senior U.S. board-certified radiologist when reviewers disagreed. Overall CAC-category agreement was 87.1%; category agreement was very low 95.1%, low 81.3%, medium 81.5%, and high 89.3%. These are agreement endpoints; the packet does not report sensitivity, specificity, or AUC.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Four-category coronary artery calcification (CAC) assessment of plaques on non-cardiac-gated, non-contrast CT images that include the heart; preview images are informational and the result is not for stand-alone clinical decision-making.
  • Exact FDA submission
  • Checked 2026-09-09
Workflow role
Parallel post-processing CAC categorization, quantification, and visualization support for clinician review.
  • Exact FDA submission
  • Checked 2026-09-09
Required input
Filtered routine DICOM images from non-cardiac-gated, non-contrast CT studies that include the heart in adults aged 30 years and older.
  • Exact FDA submission
  • Checked 2026-09-09
Output and clinician action
Very low, low, medium, or high CAC category corresponding to Agatston ranges 0, 1-100, 101-400, and at least 400; a preliminary report with warnings, category, and number of CAC-containing slices; and PACS images showing the represented calcium alongside original slices.
  • Exact FDA submission
  • Checked 2026-09-09
Care setting
Hospital-network clinical workflow for adults aged 30 years and older; the FDA packet does not name a narrower facility type.
  • Exact FDA submission
  • Checked 2026-09-09
Intended users
Hospital networks and appropriately trained medical specialists (physicians).
  • Exact FDA submission
  • Checked 2026-09-09
Limitations
Technically inadequate studies, including motion artifacts, severe metal artifacts, or suboptimal/inadequate field of view, are excluded; the comparison table lists axial slice thickness up to 5.0 mm and a 130 HU calcium threshold. Results are preliminary, preview images are non-diagnostic, and clinicians must review full images and other clinical information; the device is not for stand-alone decisions.
  • Exact FDA submission
  • Checked 2026-09-09
Evidence summary
FDA packet: retrospective, blinded, multicenter pivotal study of 433 cases from 6 U.S. clinical sites, with ground truth finalized by a senior U.S. board-certified radiologist when reviewers disagreed. Overall CAC-category agreement was 87.1%; category agreement was very low 95.1%, low 81.3%, medium 81.5%, and high 89.3%. These are agreement endpoints; the packet does not report sensitivity, specificity, or AUC.
  • Exact FDA submission
  • Checked 2026-09-09

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA packet: retrospective, blinded, multicenter pivotal study of 433 cases from 6 U.S. clinical sites, with ground truth finalized by a senior U.S. board-certified radiologist when reviewers disagreed. Overall CAC-category agreement was 87.1%; category agreement was very low 95.1%, low 81.3%, medium 81.5%, and high 89.3%. These are agreement endpoints; the packet does not report sensitivity, specificity, or AUC.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

BriefCase-Quantification for Coronary Artery Calcification (CAC) regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationAdult
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K231631
  • Samplen=433
  • Sites6
  • IndependenceIndependence not established

K231631

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K231631. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-09
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Filtered routine DICOM images from non-cardiac-gated, non-contrast CT studies that include the heart in adults aged 30 years and older.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-09 · FDA K231631: BriefCase-Quantification

  2. Routing

    Source context, not route validation: The FDA packet describes filtered DICOM CT input to a Linux-based cloud server and transfer of analysis to PACS or a desktop image-review application; exact local interface versions and compatibility are not established.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-09 · FDA K231631: BriefCase-Quantification

  3. AI processing

    Source context, not route validation: The exact FDA package describes BriefCase-Quantification as a single software module intended to run on a Linux-based server in a cloud environment. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "The software consists of a single module based on an algorithm programmed component and is intended to run on a linux-based server in a cloud environment.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA K231631: BriefCase-Quantification

  4. Returned objects

    Source context, not route validation: Very low, low, medium, or high CAC category corresponding to Agatston ranges 0, 1-100, 101-400, and at least 400; a preliminary report with warnings, category, and number of CAC-containing slices; and PACS images showing the represented calcium alongside original slices.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-09 · FDA K231631: BriefCase-Quantification

  5. Viewer/worklist/report

    Unresolved route: Very low, low, medium, or high CAC category corresponding to Agatston ranges 0, 1-100, 101-400, and at least 400; a preliminary report with warnings, category, and number of CAC-containing slices; and PACS images showing the represented calcium alongside original slices.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-09 · FDA K231631: BriefCase-Quantification

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes BriefCase-Quantification as a single software module intended to run on a Linux-based server in a cloud environment. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "The software consists of a single module based on an algorithm programmed component and is intended to run on a linux-based server in a cloud environment.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The FDA packet describes filtered DICOM CT input to a Linux-based cloud server and transfer of analysis to PACS or a desktop image-review application; exact local interface versions and compatibility are not established.
  • Exact FDA submission
  • Checked 2026-09-09
Security
Aidoc's current public Security & Privacy page says its security work is led by a CISO and security team, that it has adopted the NIST Cybersecurity Framework, and that its platform runs on AWS and Azure using EDR, encryption, SIEM and CSPM tooling. The page's list of standards and certifications did not load as readable text, so no certification is stated here.
  • Vendor-wide
  • Checked 2026-10-25

Vendor-wide marketing statement, not an independent attestation. It does not establish certificate scope or expiry, the controls of this exact release, data location, retention, identity and access, or incident-response terms for a deployed configuration. Obtain these from the vendor.

Monitoring
Aidoc's security page states that its platform runs on AWS and Azure and that customer data protection is achieved with the use of EDR, encryption, SIEM, CSPM and other technologies.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement, not an attestation. The page names Aidoc's platform generally and does not scope these capabilities to any specific product release; exact-release scope is not established. The page lists technology categories in use; it states no uptime, alerting or response-time SLAs.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for BriefCase-Quantification; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-09
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K231631
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Anatomy
Heart and coronary arteries
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2023-11-28
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
22Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission

    No public price or quote for the exact K231631 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-09 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

8 sources - 3 history items

Source ledger

  1. FDA K231631: BriefCase-Quantification

    U.S. Food and Drug Administration - Published 2023-11-28 - Accessed 2026-09-09

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, deployment

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. BriefCase-Quantification for Coronary Artery Calcification (CAC) model card (K231631)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, limitations, evidenceSummary, anatomy, evidenceStudies

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K231631

    U.S. Food and Drug Administration - Accessed 2026-09-09

    Scope: postmarketSafety

  8. Aidoc Security & Privacy

    Aidoc Medical - Accessed 2026-10-25

    Scope: security

Research history

  1. K231631 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K241440

HealthCCSng

Nano-X AI Ltd.

Authorized purpose: Non-invasive post-processing of routine non-gated, non-contrast CT studies containing the entire heart in adults aged 30 to 85 to evaluate coronary calcified plaque and estimate coronary calcium score and category.

Modality
CT/CTA
Anatomy
Heart and coronary arteries
Decision
2024-08-19
FDA-cleared K233211

AVIEW CAC

Coreline Soft Co., Ltd.

Authorized purpose: Provides quantitative coronary-plaque analysis using Agatston scoring, RCA/LCA segmentation, and calcium-score, gender, and age percentile risk stratification.

Modality
CT/CTA
Anatomy
Heart and coronary arteries
Decision
2024-03-29
FDA-cleared K230112

CAC Software

Imbio, Inc.

Authorized purpose: Provides non-invasive post-processing to quantify possible coronary calcifications and output Agatston score, arterial age, mass, and volume.

Modality
CT/CTA
Anatomy
Heart and coronary arteries
Decision
2023-06-13
FDA-cleared K201034

Syngo.CT CaScoring

Siemens Medical Solutions USA, Inc.

Authorized purpose: syngo.CT CaScoring analyzes noncontrast standard- or low-dose cardiac CT, marks calcified coronary lesions, allocates them to the right coronary, left main, left anterior descending, or circumflex artery, and calculates artery and total Agatston-equivalent, mass, and volume scores.

Modality
CT/CTA
Anatomy
Heart and coronary arteries
Decision
2020-05-14

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history